Chameleon Biosciences Patents

Patent portfolio assigned to Chameleon Biosciences (verified via public assignee records). California gene-therapy platform (EVADER enveloped-AAV vectors). CureDuchenne is an investor/strategic partner (relationship=partner). EVADER IP is owned by Chameleon plus licensed issued IP of co-founder Casey Maguire at Mass General; has_patents=true based on company statement of owned/licensed IP, though a direct Google Patents assignee=Chameleon Biosciences hit was not confirmed; count unknown. No direct competitors sourced